Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer â Clarification
National · Effective Oct 2, 2025
1 active Medicare policy lists Q2043, and 18 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
National · Effective Oct 2, 2025
18 policies from 16 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Personalized Vaccines (e.g., Provenge) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Personalized Vaccines (e.g., Provenge) | Not recorded | Covered with conditionsInferred from policy title |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Personalized Vaccines (e.g., Provenge) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Personalized Vaccines (e.g., Provenge) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Sipuleucel-T (e.g., Provenge) for the Treatment of Prostate Cancer | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Oncology Medications | Oct 1, 2026 | Covered |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Oncology Medications | Oct 1, 2026 | Covered |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Oncology Medications | Oct 1, 2026 | Covered |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Oncology Medications | Oct 1, 2026 | Covered |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Sipuleucel-T (Provenge) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Cigna MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Sipuleucel-T (Provenge); CP.PHAR.120 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Q4 - 2026 JHP MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Sipuleucel-T (Provenge) | May 15, 2020 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| 00264 sipuleucel-T (Provenge) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Provenge | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Provenge (sipuleucel-T) Listed in Moda Health's provider indexes for Oregon, Alaska, Idaho, Texas. The document does not establish the member's state or line of business. | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of Q2043 |
|---|---|---|
| Provenge (sipuleucel-T) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |